As of November 6, 2026, 3 holders' latest Schedule 13D or 13G filings report owning 5% or more of Generate Biomedicine Inc. The largest reported stake is Flagship Pioneering, LLC's, at 48.9%. 3 filings are on record since May 15, 2026 (Schedule 13G, May 15, 2026).
Sell to companies like Generate Biomedicine Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Fmr LLC · Sole voting: 7,186,167 · Shared voting: 0 · Sole dispositive: 7,186,203 · Shared dispositive: 0 · SCHEDULE 13G, 2026-11-05
- · Reporting person: Flagship Pioneering Fund VI, L.P. · Sole voting: 0 · Shared voting: 12,723,940 · Sole dispositive: 0 · Shared dispositive: 12,723,940 · SCHEDULE 13G, 2026-05-15
- · Reporting person: Nally Michael · Sole voting: 6,919,051 · Shared voting: 0 · Sole dispositive: 6,919,051 · Shared dispositive: 0 · SCHEDULE 13G, 2026-05-15
Generate Biomedicine Inc has 3 Schedule 13D or 13G filings on record since 2026-05-15. 3 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Flagship Pioneering, LLC | 48.9% | 62,673,117 | SCHEDULE 13G, 2026-05-15 | 2026-03-31 |
| Fmr LLC | 5.6% | 7,186,203 | SCHEDULE 13G, 2026-11-05 | 2026-09-30 |
| 5.2% | 6,919,051 | SCHEDULE 13G, 2026-05-15 | 2026-03-31 |
Holding shares or following this stake? See who's behind Generate Biomedicine Inc and the warning signs.
Free to see. No signup.
Keep reading
More on Generate Biomedicine Inc and the records around it.
Generate Biomedicine Inc elsewhere on the record
Companies that share a holder
- FMR LLC also filed stake reports on 761 other companies: ASPEN NEUROSCIENCE INC (Nov 2026), AVALO THERAPEUTICS INC (Nov 2026), BRAZE INC (Nov 2026)
Watch Generate Biomedicine Inc
Get an email when Generate Biomedicine Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Generate Biomedicine Inc?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Generate Biomedicine Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Generate Biomedicine Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
7 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Flagship Pioneering Fund VI, L.P. | 0 | 12,723,940 | 0 | 12,723,940 | SCHEDULE 13G, 2026-05-15 |
| Flagship Pioneering Fund VI General Partner LLC | 0 | 12,723,940 | 0 | 12,723,940 | SCHEDULE 13G, 2026-05-15 |
| Pioneering Medicines 02, LLC | 0 | 1,562,500 | 0 | 1,562,500 | SCHEDULE 13G, 2026-05-15 |
| Flagship Pioneering Fund VII, L.P. | 0 | 16,827,224 | 0 | 16,827,224 | SCHEDULE 13G, 2026-05-15 |
| Flagship Pioneering Fund VII General Partner LLC | 0 | 16,827,224 | 0 | 16,827,224 | SCHEDULE 13G, 2026-05-15 |
| Nutritional Health LTP Fund, L.P. | 0 | 987,491 | 0 | 987,491 | SCHEDULE 13G, 2026-05-15 |
| Nutritional Health LTP Fund General Partner LLC | 0 | 987,491 | 0 | 987,491 | SCHEDULE 13G, 2026-05-15 |
| Flagship Pioneering Special Opportunities Fund II, L.P. | 0 | 2,777,752 | 0 | 2,777,752 | SCHEDULE 13G, 2026-05-15 |
| Flagship Pioneering Special Opportunities Fund II General Partner LLC | 0 | 2,777,752 | 0 | 2,777,752 | SCHEDULE 13G, 2026-05-15 |
| Fpn Ii, L.P. | 0 | 4,340,252 | 0 | 4,340,252 | SCHEDULE 13G, 2026-05-15 |
| FPN General Partner LLC | 0 | 4,340,252 | 0 | 4,340,252 | SCHEDULE 13G, 2026-05-15 |
| Flagship VentureLabs VI, LLC | 0 | 25,016,458 | 0 | 25,016,458 | SCHEDULE 13G, 2026-05-15 |
| Flagship VentureLabs VI Manager LLC | 0 | 25,016,458 | 0 | 25,016,458 | SCHEDULE 13G, 2026-05-15 |
| Flagship Pioneering, LLC | 0 | 62,673,117 | 0 | 62,673,117 | SCHEDULE 13G, 2026-05-15 |
| Afeyan Noubar | 28,798 | 62,673,117 | 28,798 | 62,673,117 | SCHEDULE 13G, 2026-05-15 |
| Fmr LLC | 7,186,167 | 0 | 7,186,203 | 0 | SCHEDULE 13G, 2026-11-05 |
| Abigail P. Johnson | 0 | 0 | 7,186,203 | 0 | SCHEDULE 13G, 2026-11-05 |
| Nally Michael | 6,919,051 | 0 | 6,919,051 | 0 | SCHEDULE 13G, 2026-05-15 |
The latest filing identifies Generate Biomedicine Inc by CUSIP 370920100 and gives its principal executive office as 101 SOUTH STREET, SUITE 900, SOMERVILLE, MA 02143 (SCHEDULE 13G, 2026-11-05).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2026-05-15 | Nally Michael | 5.2% | SCHEDULE 13G |
| 2026-05-15 | Flagship Pioneering, LLC | 48.9% | SCHEDULE 13G |
| 2026-11-05 | Fmr LLC | 5.6% | SCHEDULE 13G |
Questions about who owns Generate Biomedicine Inc
Who owns Generate Biomedicine Inc?
On this page, 3 holders' latest ownership filings report 5% or more of Generate Biomedicine Inc: Flagship Pioneering, LLC (48.9%, Schedule 13G, filed 2026-05-15), Fmr LLC (5.6%, Schedule 13G, filed 2026-11-05) and Nally Michael (5.2%, Schedule 13G, filed 2026-05-15).
Who are the largest shareholders of Generate Biomedicine Inc?
By the share each holder's latest filing reports, the largest holders of Generate Biomedicine Inc on this page are Flagship Pioneering, LLC (48.9%), Fmr LLC (5.6%) and Nally Michael (5.2%).
When did Flagship Pioneering, LLC buy into Generate Biomedicine Inc?
The filings give report dates, not purchase dates. The earliest filing from Flagship Pioneering, LLC on this page is the Schedule 13G, filed 2026-05-15, reporting 48.9%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 3 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Generate Biomedicine Inc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| February 27, 2026 | IPO filing, Form 424B4 | $16 a share | IPO filings | Source |
| February 23, 2026 | IPO filing, Form S-1/A | — | IPO filings | Source |
| February 13, 2026 | IPO filing, Form S-1/A | — | IPO filings | Source |
| February 4, 2026 | IPO filing, Form S-1 | — | IPO filings | Source |
Tools for this story
Each opens in a new tab, filled in for Generate Biomedicine Inc. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.